Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.48 |
| ▸ | USP5 | P45974 | 3/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773751 | 0.95 | EGLN1 (0.46) | EGLN1USP5BBOX1THRATHRB | |
| SCHEMBL1773687 | 0.92 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL1772698 | 0.92 | EGLN1 (0.50) | EGLN1USP5 | |
| SCHEMBL1773196 | 0.91 | EGLN1 (0.49) | EGLN1 | |
| SCHEMBL1773271 | 0.91 | EGLN1 (0.55) | EGLN1BBOX1THRATHRBSLC6A2 | |
| SCHEMBL1772871 | 0.90 | EGLN1 (0.61) | EGLN1BBOX1FTO | |
| SCHEMBL1772127 | 0.90 | EGLN1 (0.48) | EGLN1 | |
| SCHEMBL12650217 | 0.90 | EGLN1 (0.48) | EGLN1FTO | |
| SCHEMBL1773328 | 0.90 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL1773557 | 0.90 | EGLN1 (0.48) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | EGLN1 16/4885USP5 3585/4885BBOX1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.